Adeza preterm birth drug gets orphan status
If Gestiva is approved, orphan drug designation provides the opportunity for seven years of US market exclusivity. A new drug application for Gestiva, a long-acting injectable form of
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.